ALX Oncology (NASDAQ:ALXO) Rating Lowered to “Sell” at Wall Street Zen

ALX Oncology (NASDAQ:ALXO – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings raised ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.75.

Check Out Our Latest Report on ALX Oncology

ALX Oncology Stock Performance

Shares of ALXO stock opened at $1.04 on Friday. The company has a current ratio of 9.71, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average price of $1.35 and a 200 day moving average price of $1.81. The company has a market cap of $143.81 million, a P/E ratio of -0.92 and a beta of 0.61. ALX Oncology has a 12 month low of $0.86 and a 12 month high of $2.66.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of ALX Oncology during the 2nd quarter worth approximately $15,317,000. venBio Partners LLC acquired a new position in shares of ALX Oncology in the 2nd quarter valued at $26,671,201. Nantahala Capital Management LLC purchased a new position in shares of ALX Oncology in the 2nd quarter valued at $1,552,500. 5AM Venture Management LLC purchased a new position in shares of ALX Oncology in the 2nd quarter valued at $6,328,663. Finally, Orbimed Advisors LLC purchased a new position in shares of ALX Oncology in the 1st quarter valued at $5,747,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

About ALX Oncology

(Get Free Report)

ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its research centers on the CD47 immune checkpoint, a signal that can help cancer cells evade the immune system. The company’s lead candidate, evorpacept (also known as ALX148), is an investigational CD47-blocking protein designed to support the immune system’s ability to recognize and attack cancer cells. ALX Oncology has studied evorpacept in combination with other cancer treatments across several tumor types.

See Also

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.